We observed the morphologic alterations of pre-B-ALL cell lines Nalm-6 and MHH-CALL-2 and primary CD34+ BCR-ABL1− pre-B-ALL cells undergoing low dose of CC1007 treatment. This evidence concerns the gene BCR and acute lymphoblastic leukemia.